tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IPHA Stock Latest News

Innate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial
The FlyInnate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial
20d ago
IPHA
Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe Fly
Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright
1M ago
IPHA
Innate Pharma initiated with a Buy at Lucid Capital
PremiumThe Fly
Innate Pharma initiated with a Buy at Lucid Capital
1M ago
IPHA
Innate Pharma management to meet with BTIG
PremiumThe Fly
Innate Pharma management to meet with BTIG
2M ago
IPHA
Innate Pharma management to meet with BTIG
PremiumThe Fly
Innate Pharma management to meet with BTIG
2M ago
IPHA
Target initiated, Nike upgraded: Wall Street’s top analyst calls
PremiumThe FlyTarget initiated, Nike upgraded: Wall Street’s top analyst calls
2M ago
DG
HD
Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright
2M ago
IPHA
Innate Pharma SA Reports First Half 2025 Financial Results
Premium
Company Announcements
Innate Pharma SA Reports First Half 2025 Financial Results
2M ago
IPHA
Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
PremiumRatings
Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
2M ago
IPHA
Innate Pharma downgraded to Market Perform from Outperform at Leerink
PremiumThe Fly
Innate Pharma downgraded to Market Perform from Outperform at Leerink
2M ago
IPHA
Innate Pharma initiated with a Buy at BTIG
PremiumThe Fly
Innate Pharma initiated with a Buy at BTIG
4M ago
IPHA
PremiumCompany Announcements
Innate Pharma’s IPH4502 Study: A New Hope in Cancer Treatment
4M ago
IPHA
Innate Pharma presents preclinical data for IPH6501 at EHA
PremiumThe FlyInnate Pharma presents preclinical data for IPH6501 at EHA
6M ago
IPHA
Innate Pharma presents long-term follow-up data from TELLOMAK trial
Premium
The Fly
Innate Pharma presents long-term follow-up data from TELLOMAK trial
6M ago
IPHA
Innate Pharma: Navigating Challenges with Promising Pipeline and Strategic Partnerships
Premium
Ratings
Innate Pharma: Navigating Challenges with Promising Pipeline and Strategic Partnerships
7M ago
IPHA
Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright
PremiumThe Fly
Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright
7M ago
IPHA
Innate Pharma announces EUR 15M capital increase from Sanofi
PremiumThe Fly
Innate Pharma announces EUR 15M capital increase from Sanofi
7M ago
SNY
IPHA
Innate Pharma regains rights to Anket, announces potential Sanofi investment
PremiumThe Fly
Innate Pharma regains rights to Anket, announces potential Sanofi investment
7M ago
SNY
IPHA
Innate Pharma: Promising Pipeline and Strategic Developments Drive Buy Rating
PremiumRatings
Innate Pharma: Promising Pipeline and Strategic Developments Drive Buy Rating
8M ago
IPHA
Innate Pharma Reports 2024 Financial Results and Clinical Progress
PremiumCompany AnnouncementsInnate Pharma Reports 2024 Financial Results and Clinical Progress
8M ago
IPHA
Buy Rating for Innate Pharma: Lacutamab’s Breakthrough Designation and Market Potential Drive Positive Outlook
Premium
Ratings
Buy Rating for Innate Pharma: Lacutamab’s Breakthrough Designation and Market Potential Drive Positive Outlook
10M ago
IPHA
Innovative Potential of Innate Pharma’s IPH4502 in Overcoming Drug Resistance and Expanding Therapeutic Impact
Premium
Ratings
Innovative Potential of Innate Pharma’s IPH4502 in Overcoming Drug Resistance and Expanding Therapeutic Impact
10M ago
IPHA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >